INSYS Therapeutics and UC San Diego’s Center for Medicinal Cannabis Research Expand Collaboration to Include Clinical Study of Cannabidiol in Early Psychosis
INSYS Therapeutics (NASDAQ:INSY) has announced that its clinical development collaboration with the Center for Medicinal Cannabis Research (CMCR) at UC San Diego School of Medicine has expanded to include a new study to explore the effectiveness of its proprietary cannabidoil (CBD) oral solution in early psychosis.
As quoted in the press release:
The two organizations announced their collaboration in April with plans for a CMCR study of CBD from INSYS in pediatric patients with autism. As part of the collaboration, INSYS has agreed to provide its proprietary formulation of pharmaceutical-grade CBD oral solution for both CMCR studies, which are expected to start in 2019, with others under consideration.
“As a result of this new study announced today, we expect to learn whether CBD reduces symptoms and improves cognition in early psychosis,” said Kristin Cadenhead, MD, professor of psychiatry at UC San Diego. “In addition, we plan to explore the effect of CBD on the biological response to psychosocial stress, and the effect of CBD on the eating behavior induced by antipsychotic medication.” CMCR Director Igor Grant, MD, added: “Cannabinoids such as CBD deserve rigorous study into their possible value in the treatment of neuropsychiatric disorders. We are pleased that through our collaboration with INSYS we have an opportunity to advance the field.”